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Abstract
Our knowledge of the structure and function of alkaline phosphatases has increased greatly in recent years. The crystal
structure of the human placental isozyme has enabled us to probe salient features of the mammalian enzymes that differ
from those of the bacterial enzymes. The availability of knockout mice deficient in each of the murine alkaline
phosphatase isozymes has also given deep insights into their in vivo role. This has been particularly true for probing the
biological role of bone alkaline phosphatase during skeletal mineralization. Due to space constraints this mini-review
focuses exclusively on structural and functional features of mammalian alkaline phosphatases as identified by
crystallography and probed by site-directed mutagenesis and kinetic analysis. An emphasis is also placed on the
substrate specificity of alkaline phosphatases, their catalytic properties as phosphohydrolases as well as phosphodies-
terases and their structural and functional relatedness to a large superfamily of enzymes that includes nucleotide
pyrophosphatase/phosphodiesterase.
Abbreviations: ADP – adenosine diphosphate; AMP – adenosine monophosphate; AP – alkaline phosphatase; ATP –
adenosine triphosphate; cAMP – cyclic AMP; ECAP – Escherichia coli AP; GCAP – germ cell alkaline phosphatase;
GPI – glycosylphosphatidylinositol; IAP – intestinal alkaline phosphatase; iPGM – cofactor-independent phosphoglycerate
mutase; kcat – catalytic rate constant; Ki – inhibition constant; Km – Michaelis constant; NPP1 – nucleosidetriphosphate
pyrophosphohydrolase-1; Pi – inorganic phosphate; PLAP – placental alkaline phosphatase; PLP – pyridoxal-5-phosphate;
pNPP – p-nitrophenylphosphate; PPi – inorganic pyrophosphate; TNAP – tissue-nonspecific alkaline phosphatase; Vmax –
maximal velocity; Wt – wild-type
Introduction
Alkaline phosphatases (APs; EC 3.1.3.1) occur widely in
nature, and are found in many organisms from bacteria to
man [1]. With few exceptions, APs are homodimeric
enzymes and each catalytic site contains three metal ions,
i.e., two Zn and one Mg, necessary for enzymatic activity.
The enzymes catalyze the hydrolysis of monoesters of
phosphoric acid and also catalyze a transphosphorylation
reaction in the presence of large concentrations of phos-
phate acceptors. While the main features of the catalytic
mechanism are conserved comparing mammalian and
bacterial APs, mammalian APs have higher specific ac-
tivity and Km values; have a more alkaline pH optimum;
display lower heat stability; are membrane-bound and are
inhibited by L-amino acids and peptides through an
uncompetitive mechanism. These properties, however,
differ noticeably among the different mammalian AP
isozymes and are likely to reflect very different in vivo
functions. Table 1 summarizes the nomenclature, tissue
distribution and some of the functions of human and mouse
AP isozymes. Importantly, APs have homology to a large
number of other enzymes and are, thus, part of a super-
family of enzymes with some overlapping catalytic prop-
erties and substrate specificities. This mini-review will
briefly point out some of the most salient structural features
of mammalian APs and refer to their substrate specificity
and homology to other members of the nucleoside py-
rophosphatase/phosphodiesterase family of isozymes with
which APs synergize and overlap in function, particularly
during skeletal mineralization. For more information on any
aspect of APs, including their in vivo roles as defined by
gene knockout studies, the reader is referred to a recent book
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covering in depth 25 years of progress in understanding the
structure and function of mammalian APs [2].
Protein structure and functional domains
For many years the crystallographic coordinates of the
Escherichia coli AP (ECAP) [3] molecule provided the
only source of structural information on APs, but now
the three-dimensional structure of the first mammalian AP,
i.e., human placental AP (PLAP; 1EW2; http://pdbbeta.
rcsb.org/pdb/) has been solved [4]. As had been predicted
from sequence comparisons, the central core of PLAP,
consisting of an extended b-sheet and flanking a-helices, is
very similar to that of ECAP. The overall structure of
PLAP is a dimer and each monomer contains 484 residues,
four metal atoms, one phosphate ion, and 603 water mole-
cules. The two monomers are related by a two-fold crys-
tallographic axis (Figure 1). The surface of PLAP is poorly
conserved with that of ECAP with only 8% residues in
common. PLAP possesses additional secondary structure
elements, comprising an N-terminal a-helix (residues 9 to
25), an a-helix and a b-strand in a highly divergent region
(residues 208Y280) and a different organization of the small
b-sheet in domain 365Y430. In the active site, only the
residues that are essential for catalysis are preserved, i.e., the
catalytic Ser, the three metal ion sites, M1 (occupied by
Zn2+, also called Zn1), M2 (occupied by Zn2+; also called
Zn2) and M3 (occupied by Mg2+) as well as their ligands,
while most of the surrounding residues are different. Half
of the enzyme surface corresponds to three clearly iden-
tifiable regions whose sequences largely vary among hu-
man APs, and are lacking in non-mammalian enzymes, i.e.,
the long N-terminal a-helix, an interfacial flexible loop
known as the Fcrown domain_ and a fourth metal binding
domain (M4). The availability of the PLAP structure facil-
itated modeling the human germ cell AP (GCAP), intestinal
AP (IAP) and tissue-nonspecific AP (TNAP, a.k.a. liver/
bone/kidney type AP) isozymes, revealing that all the novel
features discovered in PLAP are conserved in those human
isozymes as well [5]. The active site Ser is conserved in all
species where an AP has been sequenced to-date.
Structure/function studies comparing PLAP and the
ECAP structure have found a conserved function for those
residues that stabilize the active site Zn1, Zn2 and Mg
metal ions, i.e., Asp42, His153, Ser155, Glu311, Asp316,
His320, Asp357, His358, His360 and His432 [6] (Figure
2). However, while mutations at Zn2 or Mg sites have
similar effects in PLAP and ECAP, the environment of the
Zn1 ion in PLAP is less affected by substitutions than in
ECAP. This reflects the fact that, as shown on Figure 2,
residue Glu429 is strategically positioned at the roof of the
active site cleft where it provides additional stabilization to
the active site environment, so that Zn2+ cannot easily
diffuse in or out of the PLAP molecule [6]. An additional
non-catalytic metal-binding site M4 that appears to be
occupied by calcium and that is not present in ECAP was
revealed upon solving the PLAP 3D structure [4, 7]. This
fourth metal is coordinated by carboxylates from Glu216,
Glu270 and Asp285, by the carbonyl of Phe269 and a
water molecule and this architecture is conserved in all
human and mouse APs and presumably represents a novel
feature common to all mammalian APs. However, the
structural and functional significance of this new metal site
remains to be established.
All mammalian APs have five cysteine residues (Cys101,
Cys121, Cys183, Cys467 and Cys474 in PLAP) per subunit,
not homologous to any of the four cysteines in ECAP. They
form two disulfide bonds, Cys121-Cys183 and Cys467-
Cys474, whereas the Cys101 residue remains in free form
[6]. The N-terminus of PLAP has an additional a-helix not
present in the ECAP structure and its position is removed
from the rest of the monomer, but it interacts with the second
monomer with a buried surface area of 555 A˚2, suggesting
an involvement in enzyme dimerization. Recently,
Hoylaerts et al. [8] have shown that the integrity of the
N-terminal arm, and in particular of the a-helix comprising
residues 10Y25, represents a structural requirement for the








ALPL NM_000478 TNAP Tissue-nonspecific alkaline phosphatase;
TNSALP; BliverYboneYkidney type^ AP
Developing nervous system,
skeletal tissues, liver, kidney
Bone mineralization
ALPP NM_001632 PLAP Placental alkaline phosphatase; PLALP Syncytiotrophoblast,
a variety of tumors
Unknown
ALPP2 NM_031313 GCAP Germ cell alkaline phosphatase, GCALP Testis, malignant trophoblasts,
testicular cancer
Unkown




Akp2 NM_007431 TNAP Tissue-nonspecific alkaline phosphatase;
TNSALP; BliverYboneYkidney type^ AP
Developing nervous system,
skeletal tissues, liver, kidney
Bone mineralization
Akp3 NM_007432 IAP Intestinal alkaline phosphatase, IALP Gut Fat absorption




active site to execute the intramolecular transition required
during enzyme catalysis in both PLAP and TNAP.
The top flexible loop that constitutes the crown domain
of PLAP is formed by the insertion of a 60-residue segment
(366Y430) from each monomer. It consists of two small
interacting b-sheets, each composed of three parallel
strands, and surrounded by six large and flexible loops
containing a short a-helix [4]. This region displays the
least degree of sequence conservation among mammalian
APs and isozyme-specific properties, such as the charac-
teristic uncompetitive inhibition [6, 9Y12], their variable
heat-stability [13], and their allosteric behavior [14] have
all been attributed to residue 429 located on this crown
domain (Figures 2 and 3). This domain may also mediate
the interaction between APs and extracellular matrix
proteins, such as collagens [13, 15Y17]. Another interesting
structural feature of PLAP, with no counterpart in the
ECAP structure, is Y367 (Figure 3). This residue is part of
the subunit interface in the PLAP dimer, where it protrudes
from one subunit and its hydroxyl group is located 6.1 A˚
from the phosphate and 3.1 A˚ from His432, which in turn
chelates the zinc atom Zn1 in the active site of the other
subunit. Kozlenkov et al. [6, 12] has shown that Y367,
similar to residue 429, also plays a crucial role in deter-
mining the uncompetitive inhibition properties to the mam-
malian APs but very likely also the allosteric character of
mammalian APs.
The monomer-monomer interface in PLAP has a strong
hydrophobic character in contrast to that of ECAP. Less
than 30% of the residues are involved in hydrogen-bonding
interactions, which confer flexibility on the interface. Both
the amino terminal arm and the crown domain take part in
stabilizing the AP dimeric structure [4, 5]. Hoylaerts et al.
[14] investigated whether the monomers in a given PLAP
or GCAP dimer are subject to cooperativity during catal-
ysis following an allosteric model or act via a half-of-sites
model, in which at any time only a single monomer is
Figure 1. Three-dimensional structure of PLAP. Overview of the
structure of human PLAP from the crystallographic coordinates deter-
mined by Le Du et al. [4]. Monomer A is shown in ribbon representation
and in cyan, while monomer B is shown in surface representation in
yellow. Indicated are the active site metals, Zn1, Zn2 and Mg, the novel
fourth metal site occupied by Ca, the crown domain and the amino
terminal arm. The relative location of the GPI anchor on the processed
enzyme is also indicated.
Figure 2. Comparison of the residues coordinating to the active site metals in PLAP and ECAP. The upper panels focus on the environment of the Zn1
and Zn2 metal sites and their ligands while the lower panels display the environment of the Mg metal site and its ligands. Water molecules are shown as
red spheres. Green dotted lines denote metalYligand interactions and hydrogen bonds. The figure is taken from Kozlenkov et al. [6] and is reproduced
with permission from the Journal of Biological Chemistry.
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operative. The authors used wt, single and double mutant
PLAP homodimers and heterodimers for the analysis and
found that mammalian APs are non-cooperative allosteric
enzymes, but the stability and catalytic properties of each
monomer are controlled by the conformation of the second
AP subunit. The 3D structure of PLAP determined by Le Du
et al. [4] contributed the visualization of the residues
postulated to be involved in conferring the allosteric
character to PLAP. The allosteric behavior is probably
further favored by the quality of the dimer interface, by the
long N-terminal a-helix from one monomer that embraces
the other subunit, and by the protrusion of Tyr367 from
one monomer into the active site of the other.
Recently, Llinas et al. [18] identified a novel, non-cata-
lytic peripheral site on the surface of PLAP. This newly
identified peripheral site is 28 A˚ from the active site but
only 13 A˚ from the calcium binding site. The residues that
constitute this site are located on two a-helices, 250Y257
and 287Y297. The loop between Ser257 and Ser287 contains
the three residues that coordinate the Ca2+ ion, namely
Phe269, Glu270, and Asp285 located only two residues
from Ser287. Arg250 is located two residues away from
Trp248 that interacts with the Ca2+ through a water
molecule. Therefore, the large loop, comprising residues
250Y297, that belongs to the peripheral domain of PLAP
includes both the M4 site, and the peripheral binding site.
The location of the Ca2+ ion in this loop suggests that the
function of this novel M4 site could be related to the con-
formational stabilization of the two a-helices that form the
peripheral site.
Finally, while ECAP is located in the periplasmic space
of the bacterium, mammalian APs are ectoenzymes bound
to the plasma membrane via a glycosyl-phosphatidylinosi-
tol (GPI) anchor [19]. The GPI-glycan moiety, with general
structure Protein-(ethanolamine-PO4-6Mana1-2Mana1-
6Mana1-4 GlcN1-6myo-inositol-1-P-lipid, is added post-
translationally to the nascent PLAP peptide chain in a
transamidation reaction that involves the removal of a
stretch of 29 hydrophobic amino acids from the COOH-
terminus and the concomitant transfer of the preassembled
GPI anchor to the new carboxyterminal amino acid, Asp484
in PLAP [20]. To-date, all mammalian APs are thought to
be anchored to the plasma membrane with each monomer
carrying one unit of the GPI anchor.
Substrate specificities
Mammalian APs have broad substrate specificity and are
able to hydrolyze or transphosphorylate a wide variety of
phosphated compounds in vitro. However only a select few
of those compounds have to-date been confirmed to serve
as natural substrates for some of the AP isozymes. It has
been proposed that the role of TNAP in the bone matrix is
to generate the Pi needed for hydroxyapatite crystallization
[1, 21, 22]. However, TNAP has also been hypothesized to
hydrolyze the mineralization inhibitor PPi to facilitate min-
eral precipitation and growth [1, 23Y25]. In fact, an inborn-
error-of metabolism affecting the function of TNAP,
hypophosphatasia, leads to severe rickets and osteomalacia
[26]. Recent studies have provided compelling proof that a
major function of TNAP in bone tissue consists in hydro-
lyzing PPi to maintain a proper concentration of this min-
eralization inhibitor to ensure normal bone mineralization.
The nucleosidetriphosphate pyrophosphohydrolase activity
of NPP1 and the transmembrane PPi-channeling protein
ANK are responsible for supplying the larger amount of
PPi to the extracellular spaces. Since mice deficient in
TNAP (Akp2j/j mice) display high extracellular PPi
levels, which lead to osteomalacia, Milla´n and colleagues
[27, 28] tested the hypothesis that affecting the function of
either NPP1 or ANK would have beneficial consequences
on hypophosphatasia by reducing the amounts of extracellu-
lar PPi in the Akp2
j/j mice and conversely that affecting
the function of TNAP should also ameliorate the soft tissue
ossification in the Enpp1j/j and ank/ank mutant animals.
Indeed, experiments to rescue these abnormalities by
combining two mutations, i.e., [Akp2j/j; Enpp1j/j] and
[Akp2j/j; ank/ank] revealed that both double mutants
led to improvement of hypophosphatasia as well as of the
Figure 3. Location and environment of the Glu429 and Tyr367 residue.
Upper panel ) Top view of the entrance to the active site, showing the
position of the Y367 residue from one subunit (wireframe representation)
in the immediate vicinity of the Glu429 residue of the other subunit
(spacefill representation). Lower panel ) Detail of the active site entrance
in spacefill representation showing the location of Glu429 relative to Zn1
and the active site PO4
3j in one subunit and the relative location of Tyr367
of the other subunit. The upper panel was taken from Kozlenkov et al. [6]
and is reproduced with permission from the Journal of Biological
Chemistry.
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ossification of the vertebral apophyses confirming a major
role of TNAP in regulating extracellular PPi levels
[27, 28].
Pyridoxal-50-phosphate (PLP) has also been shown to be
a physiological substrate for the TNAP present in leuko-
cytes [29, 30]. TNAP isolated from human SAOS-2 osteo-
sarcoma cells hydrolyses phosphoethanolamine and PLP at
physiologic pH [31]. Abnormalities in PLP metabolism
also explain the epileptic seizures experienced by some
patients with hypophosphatasia [26, 32]. Other described
substrates include monofluorophosphate that can also be
hydrolyzed by TNAP [33]. Human AP isozymes are able to
hydrolyze phosphatidates with various fatty acyl chains
(egg phosphatidate and dioleoyl, distearoyl, dipalmitoyl,
dimyristoyl and dilauroyl phosphatidates). PLAP and IAP
were capable of hydrolyzing all the phosphatidates exam-
ined with maximal activity in the presence of 10 g/l sodium
deoxycholate and dilauroyl phosphatidate being the best
substrate. The phosphatidate hydrolytic activity of PLAP
was twoYthree times higher than that of the IAP enzyme,
while TNAP did not hydrolyze phosphatidates with long
fatty acyl chains (C16Y18) even in the presence of sodium
deoxycholate [34]. Inorganic polyphosphates (polyP),
being energy-rich linear polymers of orthophosphate resi-
dues known from bacteria and yeast, also exist in higher
eukaryotes. Calf IAP is able to cleave polyP molecules up
to a chain length of about 800, acting as an exopolyphos-
phatase progressively degrading polyP. The pH optimum is
in the alkaline range. TNAP was not able to hydrolyze
polyP under the conditions tested while PLAP and ECAP
displayed polyP-degrading activity [35].
APs appear also to be involved in the metabolism of
nucleotides. Say et al. [36] reported that purified osseous
plate TNAP displayed broad substrate specificity and was
able to hydrolyze ATP, ADP, AMP, PPi, glucose-1-phos-
phate, glucose-6-phosphate, fructose-6-phosphate, b-glyc-
erophosphate, bis-( p-nitrophenyl)-phosphate in addition to
pNPP. However, ATP, bis-( p-nitrophenyl)-phosphate and
PPi were among the less hydrolyzed substrates assayed.
Nevertheless, TNAP appears to be able to hydrolyze ATP
both at pH 7.5 and pH 9.4 [37]. However, Pizauro et al.
[38] concluded that the membrane-specific ATPase activity
present in osseous plate membranes and TNAP are dif-
ferent proteins. Several reports have indicated that TNAP
is involved in AMP hydrolysis [39, 40]. Extracellular ade-
nine nucleotides induce cAMP elevation through local
adenosine production at the membrane surface and subse-
quent activation of adenosine A (2A) receptors in NG108-
15 neuronal cells. NG108-15 cells hydrolyzed AMP to
adenosine and this activity was suppressed at pH 6.5, but
markedly increased at pH 8.5. The AMP hydrolysis was
also blocked by levamisole, an uncompetitive inhibitor of
TNAP [12], and the cells expressed TNAP mRNA. These
results indicated that AMP phosphohydrolase activity in
NG108-15 cells is due to TNAP, and suggest that this en-
zyme plays an essential role for the P1 antagonist-sensitive
ATP-induced cAMP accumulation in NG108-15 cells [39].
Similarly, Picher et al. [40] found that two ectonucleoti-
dases mediated the conversion of AMP to adenosine on the
mucosal surface of human airway epithelia, i.e., ecto 50-
nucleotidase (CD73) and TNAP. While both mucosal and
serosal epithelial surfaces displayed ecto 50-nucleotidase
activity, TNAP activity was restricted to the mucosal surface.
These experiments support a major role for extracellular
nucleotide catalysis and for the involvement of TNAP in the
regulation of adenosine concentrations on airway surfaces.
Other catalytic properties of APs are also worth men-
tioning. AP isolated from the mouse intestine is able to
catalyze the synthesis of PPi from Pi during hydrolysis of
glucose 6-phosphate, ATP, ADP, PPi or pNPP [41]. While
the rate of PPi synthesis is 1,000-fold lower than the rate of
substrate hydrolysis, PPi synthesis increased by the ad-
dition of Mg2+ and also by decreasing the pH from 8.5 to
6.0. The data indicated that at the catalytic site of APs the
energies of hydrolysis of the phosphoserine residue and of
PPi are different from those measured in aqueous solutions.
In another study, calf IAP was found to be able to effec-
tively transphosphorylate thiamin to thiamin monophos-
phate using b-glycerophosphate or creatine phosphate as
phosphate donors at pH 8.5. TMP production in the brush
border membrane however was very small and corresponded
to 0.001Y0.01% of the total Pi simultaneously released by
hydrolytic activity [42].
Rezende et al. [43] reported phosphodiesterase activity
as a novel property of osseous plate TNAP. Bis-( p-nitro-
phenyl)-phosphate was hydrolyzed at both pH 7.5 and 9.4
with an apparent dissociation constant of 1.9 and 3.9 mM,
respectively. The hydrolysis of p-nitrophenyl-50-thymidi-
nephosphate followed hyberbolic kinetics with a K0.5 of
500 mM. The hydrolysis of cAMP by the enzyme followed
more complex kinetics, showing site-site interactions (h =
1.7) and K0.5 = 300 mM for high-affinity sites. ATP and
cAMP were competitive inhibitors of bis-( p-nitrophenyl)-
phosphatase activity of the enzyme and Ki values (25 and
0.6 mM for cAMP and ATP, respectively) very close to
those of the K0.5 (22 and 0.7 mM for cAMP and ATP,
respectively), determined by direct assay, indicated that
a single catalytic site was responsible for the hydrolysis
of both substrates. The alkaline apparent pH optima, the
requirement for bivalent metal ions and the inhibition by
methylxanthines, amrinone and amiloride demonstrated that
rat osseous plate TNAP was a type I phosphodiesterase [43].
More recently, Zhang et al. [44] suggested that TNAP,
together with NPP1, could contribute to the pool of extra-
cellular PPi via its phosphodiesterase activity. So, it is
possible that TNAP both degrades and produces PPi but
the relative significance for skeletal mineralization of this
hypothetical dual role still remains to be clarified. Various
in vitro studies have also led to the suggestion that APs
may function as a plasma membrane phosphoprotein phos-
phatase. Sarrouilhe et al. [45] used purified rat liver plasma
membranes to study endogenous phosphorylation and de-
phosphorylation events and detected an 18-kDa phosphopro-
tein as a potential substrate for TNAP. Fedde et al. [46],
however, compared the phosphorylation of plasma mem-
brane proteins from control fibroblasts to those from pro-
foundly TNAP-deficient fibroblasts of hypophosphatasia
patients. They found no consistent different among all
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identifiable plasma membrane phosphoproteins in the con-
trol and hypophosphatasia samples and concluded that
TNAP does not modulate the phosphorylation of plasma
membrane proteins. Scheibe et al. [47] also showed that a
98-kDa membrane protein, autophosphorylated via its en-
dogenous ectokinase activity, was dephosphorylated by
TNAP in both murine P19 teratocarcinoma and HL-60
human myelopblastic leukemic cells. So, a putative role for
APs as phosphoprotein phosphatases remains an open
question at this point in time.
APs as members of a superfamily of enzymes
Of interest is the fact that APs appear to have structural
similarity to a large number of other enzymes. Cofactor-
independent phosphoglycerate mutase (iPGM) (EC 5.4.2.1)
has been previously identified as a member of the AP
superfamily of enzymes, based on the conservation of the
predicted metal-binding residues [48]. Iterative homology
searches resulted in the identification of similarly con-
served regions in phosphopentomutases (EC 5.4.2.7), APs
(EC 3.1.3.1) and in several previously uncharacterized
proteins. All the amino acid residues that interact with Zn1
(Asp327, His331, and His412) and Zn2 (Asp51, Asp369,
and His370) in ECAP [3] (Figure 2) are absolutely
conserved in phosphocarbohydrate-binding proteins of the
AP superfamily [48]. On the other hand, the ligands to the
Mg site of ECAP are much less conserved, since an E322N
substitution is found in phosphopentomutases and iPGMs,
while Asp153 and Thr155 do not seem to be conserved at
all. The strong conservation of the metal-binding residues
in both phosphopentomutase and iPGM indicates that both
these enzymes are metal dependent. Structural alignment
of iPGM with ECAP and cerebroside sulfatase confirmed
that all these enzymes have a common core structure and
revealed similarly located conserved Ser (in iPGM, ECAP
and mammalian APs) or Cys (in sulfatases) residues in
their active sites. In ECAP and mammalian APs, this Ser
residue is phosphorylated during catalysis, whereas in sul-
fatases the active site Cys residue is modified to formyl-
glycine and sulfatated. Similarly located Thr residue forms
a phosphoenzyme intermediate in phosphodiesterase/
nucleotide pyrophosphatase-1 (NPP1). In fact, APs are
known to have phosphotransferase and also phosphodies-
terase [43] activities, while iPGM and NPP1 can also
function as phosphatases [49, 50]. Using structure-based
sequence alignment, Galperin and Jedrezjas [51] identi-
fied homologous Ser, Thr, or Cys residues in other en-
zymes of the AP superfamily, such as phosphopentomutase,
phosphoglycerol transferase, phosphonoacetate hydrolase,
and GPI-anchoring enzymes (GPI- phosphoethanolamine
transferases). Thus, this AP superfamily includes enzymes
with substantially different activities (isomerases, hydro-
lases, and a putative lyase), which, however, all act on sim-
ilar phosphocarbohydrate (or sulfocarbohydrate) substrates.
While these bioinformatics studies were done using the
ECAP structure as paradigm, the same structural similarity
is bound to exist with the mammalian APs since as discussed
the active site of mammalian APs is well-conserved with
that of ECAP. The authors predict that the catalytic cycles of
all the members of this superfamily involve phosphoryla-
tion, or sulfatation, or phosphonation of these conserved
Ser/Thr/Cys residues. This would imply that all enzymes of
the AP superfamily would have the same reaction scheme
(Scheme 1) where phosphate (sulphate or phosphonate)
acceptor can be either water (r2 = H, in phosphatases, sul-
fatases, phosphonate hydrolases) or a second substrate (in
phosphoglycerol and phosphoethanolamine transferases)
or just a different hydroxyl group of the same original sub-
strate r1 (in iPGM and phosphopentomutase).
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